ORTOLAN, AUGUSTA
 Distribuzione geografica
Continente #
NA - Nord America 4.383
AS - Asia 2.457
EU - Europa 1.493
AF - Africa 610
SA - Sud America 530
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 37
AN - Antartide 1
Totale 9.572
Nazione #
US - Stati Uniti d'America 4.054
SG - Singapore 988
CN - Cina 365
IT - Italia 325
BR - Brasile 302
HK - Hong Kong 298
VN - Vietnam 163
DE - Germania 162
PL - Polonia 81
FI - Finlandia 78
FR - Francia 76
GB - Regno Unito 68
SE - Svezia 68
RU - Federazione Russa 58
NL - Olanda 55
BJ - Benin 54
IN - India 54
AR - Argentina 43
MX - Messico 42
CA - Canada 39
TR - Turchia 35
ES - Italia 34
IE - Irlanda 34
ZA - Sudafrica 32
AT - Austria 29
IQ - Iraq 28
CO - Colombia 26
EC - Ecuador 26
RO - Romania 26
UY - Uruguay 26
AE - Emirati Arabi Uniti 25
JP - Giappone 25
UA - Ucraina 25
AU - Australia 23
BA - Bosnia-Erzegovina 23
PA - Panama 23
ID - Indonesia 22
PT - Portogallo 22
TW - Taiwan 22
AL - Albania 21
CL - Cile 21
EE - Estonia 21
IL - Israele 21
JM - Giamaica 21
NP - Nepal 21
PE - Perù 21
PS - Palestinian Territory 21
CZ - Repubblica Ceca 20
GM - Gambi 20
JO - Giordania 20
PY - Paraguay 20
SI - Slovenia 20
UZ - Uzbekistan 20
CM - Camerun 19
CR - Costa Rica 19
CW - ???statistics.table.value.countryCode.CW??? 19
IR - Iran 19
KZ - Kazakistan 19
SA - Arabia Saudita 19
AZ - Azerbaigian 18
GA - Gabon 18
GE - Georgia 18
HU - Ungheria 18
NG - Nigeria 18
TJ - Tagikistan 18
VE - Venezuela 18
EG - Egitto 17
GT - Guatemala 17
HR - Croazia 17
KH - Cambogia 17
MA - Marocco 17
MG - Madagascar 17
MK - Macedonia 17
MY - Malesia 17
PH - Filippine 17
SO - Somalia 17
XK - ???statistics.table.value.countryCode.XK??? 17
BZ - Belize 16
CV - Capo Verde 16
CY - Cipro 16
GF - Guiana Francese 16
NO - Norvegia 16
PR - Porto Rico 16
SN - Senegal 16
TZ - Tanzania 16
BY - Bielorussia 15
CD - Congo 15
DZ - Algeria 15
LY - Libia 15
ME - Montenegro 15
TH - Thailandia 15
YT - Mayotte 15
BS - Bahamas 14
BW - Botswana 14
DJ - Gibuti 14
KR - Corea 14
MD - Moldavia 14
MN - Mongolia 14
MU - Mauritius 14
RS - Serbia 14
Totale 8.939
Città #
Fairfield 609
Ashburn 605
Singapore 534
Chandler 326
Hong Kong 276
Woodbridge 251
Cambridge 233
Houston 217
Seattle 200
Beijing 136
Ann Arbor 133
Wilmington 132
Boardman 86
Santa Clara 82
Los Angeles 73
Ho Chi Minh City 64
Munich 60
San Diego 60
Princeton 56
Padova 55
Cotonou 53
Medford 52
Bytom 45
New York 38
Des Moines 36
Helsinki 35
Milan 35
Rome 35
Chicago 32
Roxbury 30
Hanoi 29
São Paulo 29
Dublin 25
Vienna 23
Montevideo 22
Amsterdam 21
London 21
Nanjing 21
Panama City 20
Guangzhou 18
Libreville 18
Willemstad 18
Amman 17
Baku 17
Falkenstein 17
Kingston 17
Orem 17
Dakar 16
Dushanbe 16
Lappeenranta 16
Lima 16
Montreal 16
Tashkent 16
Baghdad 15
Chennai 15
Denver 15
Phnom Penh 15
Praia 15
Verona 15
Atlanta 14
Boston 14
Dallas 14
Nassau 14
Podgorica 14
San José 14
Ulan Bator 14
Conakry 13
Frankfurt am Main 13
Hefei 13
Nouakchott 13
Tallinn 13
Antananarivo 12
Buffalo 12
Harare 12
Hargeisa 12
Kigali 12
Tbilisi 12
Tokyo 12
Zagreb 12
Abidjan 11
Bamako 11
Brasília 11
Cayenne 11
Dubai 11
Havana 11
Johannesburg 11
Kinshasa 11
Lisbon 11
Ljubljana 11
Luanda 11
Lusaka 11
Nairobi 11
Turku 11
Warsaw 11
Castries 10
Chisinau 10
Dar es Salaam 10
Lagos 10
Niamey 10
Riga 10
Totale 5.599
Nome #
Serological Biomarkers in Early Axial Spondyloarthritis During 24-Months Follow Up (Italian Arm of Space Study) 217
Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. 215
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 210
Erosive hand osteoarthritis: latest findings and outlook 208
Serological markers of erosive hand osteoarthritis 198
A recently developed MRI scoring system for hand osteoarthritis: its application in a clinical setting 197
Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study 190
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab 190
The controversial relationship between osteoarthritis and osteoporosis: an update on hand subtypes 187
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients 180
Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients 174
Biomarkers, imaging and disease activity indices in patients with early axial spondyloarthritis: The Italian arm of the SpondyloArthritis-Caught-Early (SPACE) Study 174
Molecular mechanisms of pain in crystal-induced arthritis 171
Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort 169
Infection relapse in spondyloarthritis treated with biological drugs: A single-centre study 167
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis 167
Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment 166
Spine and sacroiliac joints on magnetic resonance imaging in patients with early axial spondyloarthritis: Prevalence of lesions and association with clinical and disease activity indices from the italian group of the SPACE study 165
IL TREAT-TO-TARGET NELLA REAL-LIFE IN PAZIENTI AFFETTI DA ARTRITE PSORIASICA 163
Serological markers in psoriatic arthritis: promising tools 161
Severe Abdominal Pain as a Manifestation of Pseudogout in Pubic Symphysis 158
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study 158
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 157
Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort 155
Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis 152
Subclinical enthesopathy of the midfoot: could it be a peculiar feature in early psoriatic arthritis? 149
Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid 146
An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision 142
Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients 141
The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review 141
Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: An observational study from the SPACE cohort 140
Bone edema of the whole vertebral body: an unusual case of spondyloarthritis 140
Efficacy and Safety of Ultrasound-Guided Intra-articular Glucocorticoid Injection in Erosive Hand Osteoarthritis 140
The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints 139
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort 138
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study 137
Validation of the italian version of the educational needs assessment tool in rheumatoid arthritis patients and factors associated with educational needs 135
Acute joint swelling in psoriatic arthritis: Flare or “psout”—A 10-year-monocentric study on synovial fluid 133
Psoriasis and Imaging Progression in early Axial Spondyloarthritis: Results from a 48-month follow-up (Italian arm of SPACE study) 132
The impact of diet on disease activity in spondyloarthritis: A systematic literature review 131
Relationship between sex and clinical and imaging features of early axial spondyloarthritis: results from a 48 month follow-up (Italian arm of the SPondyloArthritis Caught Early (SPACE) study) 131
Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis 131
Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study 131
Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study 129
Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis 128
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update 125
Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement 121
Unusual ossification: psoriatic arthritis or not? 120
Predictors of disease activity in gout: a 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study 119
Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy 118
The Risk of overdiagnosis and overtreatment in spondyloarthritis 117
Spine and Sacroiliac Joints Lesions on Magnetic Resonance Imaging in Early Axial-Spondyloarthritis During 24-Months Follow-Up (Italian Arm of SPACE Study) 116
Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 116
Impact of disease duration and gender on the sensitivity and specificity of 2015 ACR/EULAR classification criteria for gout. Cross-sectional results from an Italian multicentric study on the management of crystal-induced arthritis (ATTACk) 116
External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomised clinical trials of ixekizumab 110
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort 109
Do we believe in non-radiographic axial spondyloarthritis? A debate 103
Identification in synovial fluid of a new potential pathogenic player in arthropathies 102
Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers 101
Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. 101
Search for Galactic axions with a high- Q dielectric cavity 98
SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology 96
Clinical vignette: a rare presentation of a first gout flare 88
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis 87
Answer to Ben Nessib et al. Joint Bone Spine 2023;90:105539 87
Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study 78
Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply 62
Le malattie autoimmuni 60
Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable 58
Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis 55
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis 47
null 3
Totale 9.696
Categoria #
all - tutte 32.708
article - articoli 32.211
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 178
Totale 65.097


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021574 0 0 0 0 0 39 15 54 65 85 73 243
2021/2022837 32 106 42 63 17 77 55 82 22 53 58 230
2022/2023587 143 72 17 65 80 52 3 37 55 13 17 33
2023/2024527 10 47 54 60 33 62 40 53 37 28 43 60
2024/20251.845 6 155 73 89 205 64 98 213 114 102 285 441
2025/20264.109 415 498 964 1.234 702 296 0 0 0 0 0 0
Totale 9.696